May 11, 2026 11:13 am (IST)
Follow us:
Aurobindo Pharma receives USFDA approval for drug related to moderate dementia
Hyderabad/Mumbai, Mar 29 (IBNS) Aurobindo Pharma Limited, which manufactures generic pharmaceuticals and active pharmaceutical ingredients, announced on Tuesday that the company has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rivastigmine Tartrate Capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg.
This product is expected to be launched in the first quarter of fiscal year 2016-17.
The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon Capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation, said the company.
Naproxen Sodium Tablets is used in the treatment of mild moderate dementia of the Alzheimer's and Parkinson's disease.
The approved product has an estimated market size of US$ 26.7 million for the twelve months ending January 2016 according to IMS.
This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing oral non-antibiotic products.
Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from USFDA.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Sensex crashes over 1,000 points as West Asia tensions rattle markets, oil prices surge
Mon, May 11 2026
AI takes over? Cloudflare cuts 1,100 jobs as AI surges
Fri, May 08 2026
Profit jumps 30%! Aditya Birla Capital posts strong Q4 FY26 results
Fri, May 08 2026
Claim Settlement Ratio Explained: How It Affects Your Policy
Thu, May 07 2026
Amidst rising input costs, manufacturing growth remains positive: FICCI Manufacturing Survey
Wed, May 06 2026
Nissan Motor India launches nationwide AC Check-up Camp to help customers stay summer-ready
Wed, May 06 2026